BIN CHEN ET AL: "Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells", PLOS ONE, vol. 10, no. 6, 10 June 2015 (2015-06-10), page e0129663, XP055218386, US ISSN: 1932-6203, DOI: 10.1371/journal.pone.0129663 (B1)

ZHANG QING ET AL: "[Effect of PI3K[delta] inhibitor CAL-101 on myeloma cell lines and preliminary study of synergistic effects with other new drugs].", ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI OCT 2014, vol. 35, no. 10, October 2014 (2014-10), pages 926-930, XP008177739, ISSN: 0253-2727 (B1)

D'CRUZ OJ ET AL: "Novel Bruton's tyrosine kinase inhibitors currently in development", ONCOTARGETS AND THERAPY, vol. 6, 6 March 2013 (2013-03-06), pages 161-176, XP055217561, GB ISSN: 1178-6930, DOI: 10.2147/OTT.S33732 (B1)

D. CHIRON ET AL: "Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma", CANCER DISCOVERY, vol. 4, no. 9, 31 July 2014 (2014-07-31), pages 1022-1035, XP055218352, US ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-14-0098 (B1)

E KLYUCHNIKOV ET AL: "Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?", BONE MARROW TRANSPLANTATION, vol. 49, no. 1, 27 May 2013 (2013-05-27), pages 1-7, XP055217963, GB ISSN: 0268-3369, DOI: 10.1038/bmt.2013.72 (B1)

G. K. PHILIPS ET AL: "Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies", INTERNATIONAL IMMUNOLOGY., vol. 27, no. 1, 16 October 2014 (2014-10-16), pages 39-46, XP055217958, GB ISSN: 0953-8178, DOI: 10.1093/intimm/dxu095 (B1)

GIROTTI MARIA ROMINA ET AL: "No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients", MOLECULAR ONCOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 8, no. 6, 15 August 2014 (2014-08-15) , pages 1140-1158, XP029054008, ISSN: 1574-7891, DOI: 10.1016/J.MOLONC.2014.07.027 (B1)

GRISAFI DAVIDE ET AL: "Ibrutinib: from bench side to clinical implications", MEDICAL ONCOLOGY, SCIENCE AND TECHNOLOGY LETTERS, NORTHWOOD, GB, vol. 32, no. 9, 30 July 2015 (2015-07-30), pages 1-10, XP035522374, ISSN: 1357-0560, DOI: 10.1007/S12032-015-0669-9 [retrieved on 2015-07-30] (B1)

HANTSCHEL O: "Targeting BCR-ABL and JAK2 in Ph+ ALL", BLOOD 20150226 AMERICAN SOCIETY OF HEMATOLOGY USA, vol. 125, no. 9, 26 February 2015 (2015-02-26), pages 1362-1363, XP008177695, ISSN: 0006-4971 (B1)

HONG D S ET AL: "A multicenter study of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors", JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, USA, vol. 36, no. 15, Supplement 1, 1 May 2018 (2018-05-01), page 2578, XP009511915, ISSN: 1527-7755, DOI: 10.1200/JCO.2018.36.15_SUPPL.2578 (B1)

IDIT SAGIV-BARFI ET AL: "Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 112, no. 9, 17 February 2015 (2015-02-17), pages E966-E972, XP055217955, US ISSN: 0027-8424, DOI: 10.1073/pnas.1500712112 (B1)

J. SCHWAMB ET AL: "B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides", BLOOD, vol. 120, no. 19, 8 November 2012 (2012-11-08), pages 3978-3985, XP055218383, US ISSN: 0006-4971, DOI: 10.1182/blood-2012-05-431783 (B1)

JENNIFER L. YORI ET AL: "Abstract LB-221: Inhibition of rapamycin-induced feedback activation of AKT with dasatinib induces complete tumor regression in a preclinical model of breast cancer.", CANCER RESEARCH, vol. 73, no. 8, Suppl. 1, 15 April 2013 (2013-04-15), - 10 April 2013 (2013-04-10), pages LB-221, XP055217951, US ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2013-LB-221 (B1)

L. A. MATHEWS GRINER ET AL: "High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 111, no. 6, 27 January 2014 (2014-01-27), pages 2349-2354, XP055218384, US ISSN: 0027-8424, DOI: 10.1073/pnas.1311846111 (B1)

QINGJIE LIU ET AL: "Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 25, no. 19, 6 August 2015 (2015-08-06), pages 4265-4269, XP055218382, AMSTERDAM, NL ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2015.07.102 (B1)

SONGDEJ NATTHAPOL ET AL: "GIST Treatment Options after Tyrosine Kinase Inhibitors", CURRENT TREATMENT OPTIONS IN ONCOLOGY MAY 2005, SPRINGER US, BOSTON, vol. 15, no. 3, 22 June 2014 (2014-06-22), pages 493-506, XP035381545, ISSN: 1527-2729, DOI: 10.1007/S11864-014-0295-3 [retrieved on 2014-06-22] (B1)

STEPHENS DEBORAH M ET AL: "Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype", BLOOD, vol. 122, no. 21, November 2013 (2013-11), page 2872, XP008177696, & 55TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; NEW ORLEANS, LA, USA; DECEMBER 07 -10, 2013 (B1)

VAN DEN AKKER EMILE ET AL: "The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity", BIOLOGICAL CHEMISTRY, vol. 385, no. 5, May 2004 (2004-05), pages 409-413, XP008177694, ISSN: 1431-6730 (B1)

WO-A1-2013/010868 (B1)

WO-A1-2015/061752 (B1)

BRIAN J. PARK ET AL: "Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines - Lessons for design of combination targeted therapy", CANCER LETTERS, vol. 320, no. 1, 2 February 2012 (2012-02-02), pages 104-110, XP055217954, US ISSN: 0304-3835, DOI: 10.1016/j.canlet.2012.01.039 (B1)